The case for & against
Bull & Bear analysis
Bearish
PAVmed Inc. (NASDAQ: PAVM) is a medical technology company focused on developing innovative medical devices aimed at enhancing patient outcomes, primarily in vascular access and diagnostic technologies. Notable subsidiaries include Lucid Diagnostics, which specializes in cancer detection, and Veris Health, which is developing implantable medical devices. Positioned in the medical device space, particularly amidst rising trends in telehealth and diagnostics, PAVmed seeks to disrupt traditional healthcare models through advanced technologies and strategic partnerships.
Bull says
- ↑Q2 GAAP net loss shrank to $6.6M from $12.3M YoY, improving efficiency
- ↑Lucid processed 2,770 tests for $1.5M revenue with draft Medicare coverage
- ↑OSU partnership accelerates Veris platform enrollment for commercial rollout
- ↑Port IO may use 510(k) pathway, potentially expediting 2027 launch
- ↑Planned $30M Series D raise extends cash runway for R&D and growth
- ↑Preventive healthcare and telehealth tailwinds support subsidiary markets
Bear says
- ↓Negative earnings yield and profitability scores highlight value-trap risk
- ↓Q2 cash of $3.78M versus $6.6M burn relies on future warrant proceeds
- ↓High short interest reflects skeptical market sentiment
- ↓FDA approval delays for Port IO could push commercialization beyond 2027
- ↓Heavy dependence on partnerships and regulatory outcomes adds execution risk
- ↓Negative momentum and small size factors may deter investors
Earnings Call · Q2 2025 · Mgmt. Guidance
Updated 08-16-2026bullish
Transcript signals
Bull points
- the laboratory has plenty of excess capacity, five-fold capacity, even within the physical location with very minimal additional personnel that would be required to increase that capacity.
- The bulk of the manufacturing right now is happening on our high-volume manufacturer coastline in Tijuana. And that can be scaled in an unlimited way.
- none of those will be in any way a limiting factor and won't require a significant capital investment to get us to be able to handle upcoming increases of volume
Bear points
- It's important to note that a pending Medicare approval decision impacts 40% to 50% of our addressable patient population, and therefore will have a significant impact on our future revenue recognition analysis.
- Our non-GAAP loss for the second quarter of 9.9 million is better sequentially by 1.2 million and better than the trailing four-quarter average of 10.5 million.
Read full transcript analysis ›